Generic Name: alectinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Genentech

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Alecensa is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small-cell lung cancer (NSCLC).

General Info

Alecensa, alectinib

Alecensa interferes with anaplastic lymphoma kinase and RET receptor tyrosine kinases, proteins that play a role in cancer cell growth.

The ALEX trial showed that Alecensa delayed disease progression more than the older ALK inhibitor Xalkori (crizotinib) in people with previously untreated ALK-positive NSCLC. Other studies showed that Alecensa had a response rate of about 40% in NSCLC patients previously treated with Xalkori. Alecensa was approved in 2015.


Dosing Info: Alecensa is taken as a capsule twice daily.

Side Effects

Common side effects include fatigue, constipation, swelling, muscle pain and anemia. More serious adverse events may include liver toxicity, lung inflammation, kidney problems and heart rhythm abnormalities. Alecensa can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 22, 2019